Search results for

A study of five U.S. allies who ended bans on gays openly serving in their militaries showed that the wide-scale disruptions feared by opponents had never materialized, says historian and study author Nathaniel Frank. He discusses his findings and what they suggest for efforts to end the Pentagon's "don't ask, don't tell" policy.

School districts across the country are trying to make classrooms more inclusive. But misinformation, sometimes spread by top elected officials, is fueling fears of a hidden agenda.

The U.S. targeted the top al-Qaida leader, showing it could track down and strike against a hard-to-find extremist figure even in a country where the U.S. has no military or diplomatic presence.

Melissa Block speaks with our regular political commentators E.J. Dionne, of the Washington Post and Brookings Institution, and David Brooks, of the New York Times.

The new House select committee looking at the strategic relationship between the U.S. and China holds its first hearing Tuesday night. Lawmakers from both parties are teaming up on bills as well.

Namazi is on a hunger strike to mark the seventh anniversary of a prisoner swap that did not include him, and calling on Biden to free detainees in Iran. His lawyer spoke with NPR about those efforts.

Can the 49ers' seventh-round rookie QB lead them to the Super Bowl? Did the Eagles' Christmas album put them on Santa's nice list? And just how fast is it possible to recover from a high ankle sprain?

In an extended interview with NPR, Eric Holder blamed Congress for blocking the New York trial of the accused masterminds of the Sept. 11 attacks. He said terrorism was the Justice Department's top priority, and "deplored" the release of the WikiLeaks memos.

The magazine hasn't hit newsstands, but some say it glorifies alleged Boston bomber Dzhokhar Tsarnaev. Rolling Stone's editor stands by the use of the photo to help tell the story of "an incredibly normal kid" who turned into "a monster."

The Republican tax plan could reduce or eliminate federal tax credits that reward companies for developing drugs to treat rare diseases. People who benefit from the medicines have objected.